Chardan Capital Predicts MeiraGTx FY2025 Earnings

MeiraGTx Holdings plc (NASDAQ:MGTX) – Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for MeiraGTx in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings of $0.25 per share for the year. Chardan Capital has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $21.39 million for the quarter, compared to analysts’ expectations of $1.50 million. MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%.

Separately, Royal Bank of Canada boosted their target price on shares of MeiraGTx from $11.00 to $13.00 and gave the stock an “outperform” rating in a research note on Monday, March 17th.

MeiraGTx Price Performance

MeiraGTx stock opened at $7.39 on Wednesday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The company’s fifty day moving average price is $6.81 and its 200 day moving average price is $6.03. The stock has a market capitalization of $582.74 million, a P/E ratio of -6.11, a P/E/G ratio of 0.37 and a beta of 1.23. MeiraGTx has a 1 year low of $3.85 and a 1 year high of $8.75.

Insider Activity at MeiraGTx

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $6.29, for a total value of $150,960.00. Following the completion of the sale, the chief financial officer now directly owns 849,947 shares in the company, valued at $5,346,166.63. This represents a 2.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alexandria Forbes sold 35,839 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the completion of the sale, the chief executive officer now directly owns 1,395,102 shares of the company’s stock, valued at $9,026,309.94. This trade represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.40% of the stock is owned by corporate insiders.

Institutional Trading of MeiraGTx

Several hedge funds have recently made changes to their positions in MGTX. BNP Paribas Financial Markets lifted its holdings in MeiraGTx by 142.5% in the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock valued at $39,000 after acquiring an additional 5,476 shares during the last quarter. Knoll Capital Management LLC purchased a new stake in MeiraGTx in the third quarter valued at $5,212,000. Erste Asset Management GmbH purchased a new stake in MeiraGTx in the third quarter valued at $2,795,000. Garden State Investment Advisory Services LLC acquired a new position in shares of MeiraGTx in the 3rd quarter valued at $1,636,000. Finally, State Street Corp grew its holdings in shares of MeiraGTx by 0.9% during the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock worth $2,397,000 after purchasing an additional 5,251 shares during the period. Hedge funds and other institutional investors own 67.48% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.